Neumora Therapeutics, Inc. (NMRA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.64. The rating moved from Overbought to Oversold on August 18, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$1.64
• Last changeMoved from Overbought to Oversold on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Neumora Therapeutics, Inc. (NMRA) is an early‑stage biotech with value concentrated in its clinical programs and partnering potential. In the absence of detailed recent filings, financial runway and dilution risk remain primary short‑term concerns. Market conditions are currently modestly supportive for growth names, which could produce limited near‑term upside, but downside remains significant without positive clinical or commercial news. Key catalysts will be clinical readouts, partnership/licensing announcements, and any clarity on capital resources; conversely, trial delays, regulatory hurdles, or financing needs would pressure the shares.

Key factors

• Early‑stage biotech profile with clinical and pipeline focus driving long‑term value; outcomes of ongoing or upcoming studies are primary value drivers
• Limited recent public filings or financial detail available in the provided data, increasing uncertainty around cash runway and near‑term financing needs
• Sector tailwinds for biologics and CDMO/CRO demand could indirectly benefit partners and contract opportunities
• Current market tone is mildly risk‑on and growth‑friendly, which can support short‑term upside in small‑cap biotechs
• Management execution, partnerships, and any near‑term clinical readouts or licensing activity would materially affect share value

Risks

• Clinical trial failures or delayed readouts that materially reduce probability of commercialization
• High cash burn and potential for dilutive financing if cash runway is limited
• Regulatory setbacks or slower-than-expected approvals for any pipeline candidates
• Intense competition in neuroscience/biotech therapeutic areas and rapid entrant innovation
• Low liquidity and high share‑price volatility typical of small‑cap biotech names
• Negative shifts in biotech investor sentiment or a broader market risk‑off episode that reduces appetite for speculative names

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.